B. Riley Cuts Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target to $3.00

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price objective reduced by B. Riley from $4.00 to $3.00 in a report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock. B. Riley also issued estimates for Lineage Cell Therapeutics’ Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2027 earnings at ($0.08) EPS.

Several other brokerages also recently issued reports on LCTX. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. D. Boral Capital reiterated a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. Finally, Maxim Group lowered their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Lineage Cell Therapeutics presently has an average rating of “Buy” and an average target price of $4.20.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN:LCTX opened at $0.52 on Friday. The company’s 50 day moving average is $0.60. The company has a market capitalization of $114.62 million, a price-to-earnings ratio of -4.33 and a beta of 1.21. Lineage Cell Therapeutics has a 52 week low of $0.48 and a 52 week high of $1.61.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP acquired a new stake in shares of Lineage Cell Therapeutics during the 3rd quarter valued at $84,000. MAI Capital Management lifted its holdings in shares of Lineage Cell Therapeutics by 2.2% during the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock valued at $1,516,000 after purchasing an additional 35,907 shares during the last quarter. Raffles Associates LP boosted its position in shares of Lineage Cell Therapeutics by 3.4% in the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock valued at $4,081,000 after purchasing an additional 150,000 shares during the period. State Street Corp increased its stake in Lineage Cell Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,608,352 shares of the company’s stock worth $2,361,000 after purchasing an additional 45,483 shares in the last quarter. Finally, Barclays PLC raised its holdings in Lineage Cell Therapeutics by 311.3% during the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after buying an additional 159,924 shares during the period. 62.47% of the stock is currently owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.